Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Even two pens used for GLP1 medications can have different cues
TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026 : average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension
GI issues impact adherence
Thats where a telehealth option helps
W STEP-1 (RCT wieloorodkowy, faza 3) raportowano redni redukcj masy ciaa o okoo 14,9% przy 68 tygodniach interwencji semaglutydem 2,4 mg tygodniowo vs placebo
